Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Overall survival similar in mRCC trials regardless of geographic regions
J Global Oncol. 2018 Jan 17. Fay AP et al.
Key clinical point: The potential differences in clinical outcomes may be contributed by differences in access to clinical trials, disease biology, reporting of adverse events, and quality of care.
Major finding: Patient characteristics differed according to geographic region. No statistically significant differences in OS were observed when the United States/Canada (USC) was compared with other regions: Latin America, Asia/Oceania/Africa, and Eastern Europe.
Study details: Pooled retrospective analysis of 4,736 patients who had mRCC treated between 2003 and 2013 and were enrolled in phase 2 and phase 3 clinical trials.
Disclosures: The study was funded by Pfizer and in part by the Dana Farber/Harvard Cancer Center. All of the study authors reported conflicts of interest involving the sponsor, Pfizer, or other pharmaceutical companies.
Fay AP et al. J Global Oncol. 2018 Jan 17. doi: 10.1200/JGO.17.00119